{
    "organizations": [],
    "uuid": "aae9b9aa5c501c8a215b500073c385bb52484d73",
    "author": "",
    "url": "https://www.reuters.com/article/brief-corcept-therapeutics-receives-lett/brief-corcept-therapeutics-receives-letter-on-saying-teva-pharmaceuticals-usa-submitted-an-abbreviated-new-drug-application-idUSFWN1PV0X2",
    "ord_in_thread": 0,
    "title": "BRIEF-Corcept Therapeutics Receives Letter on saying Teva Pharmaceuticals USA Submitted An Abbreviated New Drug Application",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 5, 2018 / 1:52 PM / in 15 minutes BRIEF-Corcept Therapeutics Receives Letter on saying Teva Pharmaceuticals USA Submitted An Abbreviated New Drug Application Reuters Staff 1 Min Read \nFeb 5 (Reuters) - Corcept Therapeutics Inc: \n* CORCEPT THERAPEUTICS - RECEIVED PARAGRAPH IV NOTICE LETTER ADVISING THAT TEVA PHARMACEUTICALS USA SUBMITTED AN ABBREVIATED NEW DRUG APPLICATION TO FDA \n* CORCEPT THERAPEUTICS - TEVA PHARMA USA SUBMITTED ANDA SEEKING AUTHORIZATION TO MANUFACTURE, USE, SELL GENERIC VERSION OF KORLYM MIFEPRISTONE TABLETS IN U.S. \n* CORCEPT THERAPEUTICS SAYS NOTICE LETTER ALLEGES THAT KORLYM PATENTS WILL NOT BE INFRINGED BY TEVAâ€˜S PROPOSED PRODUCT - SEC FILING Source text for Eikon: Further company coverage:",
    "published": "2018-02-05T15:50:00.000+02:00",
    "crawled": "2018-02-05T16:12:49.022+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "minute",
        "therapeutic",
        "receives",
        "letter",
        "saying",
        "teva",
        "pharmaceutical",
        "usa",
        "submitted",
        "abbreviated",
        "new",
        "drug",
        "application",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "corcept",
        "therapeutic",
        "inc",
        "corcept",
        "therapeutic",
        "received",
        "paragraph",
        "iv",
        "notice",
        "letter",
        "advising",
        "teva",
        "pharmaceutical",
        "usa",
        "submitted",
        "abbreviated",
        "new",
        "drug",
        "application",
        "fda",
        "corcept",
        "therapeutic",
        "teva",
        "pharma",
        "usa",
        "submitted",
        "anda",
        "seeking",
        "authorization",
        "manufacture",
        "use",
        "sell",
        "generic",
        "version",
        "korlym",
        "mifepristone",
        "tablet",
        "corcept",
        "therapeutic",
        "say",
        "notice",
        "letter",
        "alleges",
        "korlym",
        "patent",
        "infringed",
        "teva",
        "proposed",
        "product",
        "sec",
        "filing",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}